Figure 2:

Projected population-level impact of switching to 1-dose human papillomavirus (HPV) vaccination (v. no vaccination) on incidence of cervical cancer (squamous cell carcinoma) in (A) Quebec and (B) Ontario, assuming different scenarios of 1-dose efficacy and duration (HPV vaccination coverage was 85% among females and males in Quebec, and 67% and 62% among females and males in Ontario). The lines are the median result of model projections using 50 parameter sets. Supporting data are presented in Appendix 1, Tables A5 and A6, and in Figures A4 and A5. Incidence of cervical cancer was standardized to the 2015 world population.³⁵ Note: VD = vaccine duration of protection, VE = vaccine efficacy.